Interim

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, March 28, 2024
Transcoding, Internal medicine, Temple University Hospital, CFO, Oncology, Patient, RNA, University, Cancer, University of Pittsburgh, Yale School of Medicine, Baylor College of Medicine, Infection, Therapy, Harvard University, Interim, Muscular dystrophy, Yale University, Pharmacia, Pharmaceutical industry

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.

Key Points: 
  • BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
  • Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University.
  • While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients.
  • Dr. Vlock initially will serve on a part-time basis through TransCode’s arrangement with BioBridges LLC, a life sciences consulting company.

Enthusiast Gaming Partners with Playwire to Amplify Monetization Opportunities Across its Communities

Retrieved on: 
Thursday, March 28, 2024
Organization, Partnership, Chairperson, EGLX, Make, Gaming, TSX, Interim, Trailblazer, NFL, Enthusiast Gaming, Video game

“Forging this partnership with Playwire provides Enthusiast Gaming with a world class adtech platform so that we can focus on our core -- building communities, and creating and curating content and experiences that engage gamers and esports fans,” said Board Chair and Interim CEO Adrian Montgomery. “The strategic initiative to outsource our adtech is a key element of our simplified and streamlined strategy. As a result of this partnership, along with other efficiency initiatives, we are well-positioned to deliver meaningful improvement in financial performance while continuing to serve our audience and brands.”

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming'' or the “Company”) (TSX: EGLX), the leading gaming and media company in North America, today announced a multi-year partnership with leading advertising technology provider Playwire.
  • Enthusiast Gaming will leverage RAMP®, Playwire’s complete Revenue Amplification Management Platform, to power Enthusiast Gaming’s network of gaming websites, channels and apps.
  • Playwire brings nearly two decades of experience helping enterprise organizations manage multiple sites and a strong legacy in gaming.
  • This will allow Enthusiast Gaming to optimize its programmatic performance and drive incremental revenue opportunities.

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

RC Show 2024 Release New & Innovative Product Showcase

Retrieved on: 
Wednesday, March 27, 2024
Cooking, LFC, PFAS, Milk, Pineapple, Enercare Centre, Carbon, Wine, Pea, Restaurant, Creativity, Marketing, Automation, Red meat, Ginger, Drink, Miski, Hormone, VKD, Atlas, Freezing, Notch, Woman, Mouth, Safety, Interim, Cholesterol, Sambucus, Breakfast, Food, Rejuvenation, Taste, Bison, Coffee, RC, Plant, Food safety, Advertising, Farmer, Growth, ServiceNow, SoFi, Environment, Agave, Robotics, Water, Billio, MEIKO, AMT, Genetically modified organism, Tractor

Since 2010, KEENON Robotics , driven by its slogan "Keen on robots, keen on the future," has led the robotics sector.

Key Points: 
  • Since 2010, KEENON Robotics , driven by its slogan "Keen on robots, keen on the future," has led the robotics sector.
  • With a comprehensive range including advertising, delivery, hotel, and the latest addition, cleaning robots, they cater to diverse commercial needs.
  • Diversey Canada Inc. has been a pivotal player in increasing operational efficiency for the industry and that continues in 2024.
  • You will find more of these innovative products and solutions all under one roof at RC Show 2024, taking place April 8-10, where the industry will come together, be inspired and learn how to LEVEL UP!

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, March 27, 2024
Toxicity, Ovarian cancer, BRCA, Mirvetuximab soravtansine, Partnership, Patient, Neoplasm, Cancer, Merck, Doctor of Philosophy, Olaparib, WNT, Niraparib, Jiangsu Hengrui Medicine, PARP, Therapy, Safety, Platinum, Interim, Rucaparib, Pharmaceutical industry

This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.

Key Points: 
  • This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
  • In addition, stenoparib is unique in its mechanism of action, inhibiting PARP as well as the novel cancer target, tankyrase.
  • Tankyrase inhibition would restrain the WNT pathway, which is commonly upregulated not only in ovarian cancers but in many other solid cancers.
  • Given the unique, dual mechanism of action for stenoparib—coupled with its favorable safety profile—stenoparib may represent the next-generation alternative in the evolving market for advanced ovarian cancer patients.

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Retrieved on: 
Tuesday, March 26, 2024
AgeX Therapeutics, CUSIP, IND, Gibson Dunn, Therapy, Interim, ADC, FDA, LNP, DSM-IV codes, Food, Pharmaceutical industry

The combined company will operate under the name Serina Therapeutics and will trade on the NYSE American market under the ticker symbol “SER” effective with the open of business on Wednesday, March 27, 2024.

Key Points: 
  • The combined company will operate under the name Serina Therapeutics and will trade on the NYSE American market under the ticker symbol “SER” effective with the open of business on Wednesday, March 27, 2024.
  • The new CUSIP number for the combined company following the merger is 81751A108.
  • Serina Board Chair J. Milton Harris, Ph.D., stated, “This merger is the culmination of years of work on the part of the Serina team and enables us to move our lead polyoxazoline-drug conjugate into clinical trials.
  • Bradley Arant Boult Cummings LLP provided legal counsel to Serina.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Research, Consultant, Administration, Patient, Breast, Prostate, Insurance, IND, Data collection, Investment, Interim, Therapy, Research and development, FDA, NK, Pharmaceutical industry

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $1.81 million compared to $2.94 million for the same quarter in 2022.
  • Other income net of other expenses, for the fourth quarter ended December 31, 2023 was $0.21 million compared to $0.19 million for the same quarter ended December 31, 2022.
  • Net Loss: The Company reported a net loss of $2.96 million for the fourth quarter ended December 31, 2023 compared to a loss of $5.58 million for the same quarter in 2022.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Administration, CSF1R, TREM2, MRI, Data analysis, PD, CSF, Magnetic resonance imaging, Patient, Biomarker, Microglia, Osteopontin, Fluid mechanics, IGNITE, Investment, Clinical trial, Pharmacokinetics, Interim, Research and development, Data, FDA, AFL, Pharmaceutical industry

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points: 
  • “Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
  • We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
  • Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
  • The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

ABC arbitrage: 2023 Results

Retrieved on: 
Tuesday, March 26, 2024
ABC, FIA, Authority, AGM, Policy, FED, Index (economics), Investment, Ecosystem, Interim

As a result, market volumes were significantly lower, illustrated for example by a drop-off of 15% on EuroStoxx 600.

Key Points: 
  • As a result, market volumes were significantly lower, illustrated for example by a drop-off of 15% on EuroStoxx 600.
    Business Performance - The Group’s results are below ambitions but still in line with 2023 market parameters.
  • The strategies launched by the ABC 2022 business plan are below expectations for this fiscal year.
  • Group AUM remains stable (-2%) with a total amount of €336 million on 1 March 2024 (against €343 million on December 31, 2023).
  • Group AUM remains close to 2023 levels, but the latest advances give ABC arbitrage reason to expect a rebound in this area, despite the delay in 2022 and 2023.

Manatt Welcomes Leading Developmental Disability Leader to National Health Care Industry Group

Retrieved on: 
Tuesday, April 9, 2024
Public Policy, Government, Legal, General Health, Health, Consulting, Healthcare Reform, Professional Services, Other Health, Community, Face, Case management, Health equity, DHS, LLP, Private sector, Human, Manatt, Phelps & Phillips, Lawyer, Disability, Interim, Consultant, Nursing

Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, today announced the arrival of Senior Advisor Anna Lansky to the Firm’s Health Care industry group.

Key Points: 
  • Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, today announced the arrival of Senior Advisor Anna Lansky to the Firm’s Health Care industry group.
  • Most recently serving as the Interim Director of the Oregon Department of Human Services’ (DHS) Office of Developmental Disabilities Services (ODDS), Lansky will work with the Firm’s health care and state clients to align, strengthen and support care coordination efforts for their respective communities.
  • “Anna is a highly respected leader and trailblazer within the health care policy, government and regulatory arenas, making her an ideal fit for our growing integrated legal and consulting platform, especially as we continue to focus on improving the health care quality, delivery and access, and advancing health equity,” said Manatt CEO and Managing Partner Donna L. Wilson .
  • “With over 20 years of experience, including senior roles in analyzing, building and running state intellectual and developmental disability (I/DD) agencies, Anna brings a robust understanding of the core issues our clients face,” said Manatt Health Leader Bill Bernstein .